Compare Stocks: VNRX, NXTC, ALLR, and KZIA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLR Allarity Therapeutics	$1.41 +2.2%	$1.29	$0.77 ▼ $2.06	$21.96M	0.51	77,214 shs	139,628 shs
KZIA Novogen	$13.58 -19.6%	$13.47	$4.86 ▼ $17.40	$27.94M	2.16	214,586 shs	1.18 million shs
NXTC NextCure	$6.09 +1.0%	$4.63	$1.55 ▼ $15.74	$21.80M	1.27	294,482 shs	60,757 shs
VNRX VolitionRX	$0.45 -10.3%	$0.94	$0.33 ▼ $14.80	$6.84M	1.16	21.88 million shs	15.85 million shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLR Allarity Therapeutics	+2.17%	-0.70%	+21.55%	-14.02%	-11.32%
KZIA Novogen	-19.64%	+1.34%	+12.88%	+6.26%	+73.88%
NXTC NextCure	+1.00%	-3.18%	+21.31%	-1.77%	+16.22%
VNRX VolitionRX	-10.32%	+7.77%	-41.85%	-83.17%	-96.63%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLR Allarity Therapeutics	$1.41 +2.2%	$1.29	$0.77 ▼ $2.06	$21.96M	0.51	77,214 shs	139,628 shs
KZIA Novogen	$13.58 -19.6%	$13.47	$4.86 ▼ $17.40	$27.94M	2.16	214,586 shs	1.18 million shs
NXTC NextCure	$6.09 +1.0%	$4.63	$1.55 ▼ $15.74	$21.80M	1.27	294,482 shs	60,757 shs
VNRX VolitionRX	$0.45 -10.3%	$0.94	$0.33 ▼ $14.80	$6.84M	1.16	21.88 million shs	15.85 million shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLR Allarity Therapeutics	+2.17%	-0.70%	+21.55%	-14.02%	-11.32%
KZIA Novogen	-19.64%	+1.34%	+12.88%	+6.26%	+73.88%
NXTC NextCure	+1.00%	-3.18%	+21.31%	-1.77%	+16.22%
VNRX VolitionRX	-10.32%	+7.77%	-41.85%	-83.17%	-96.63%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALLR Allarity Therapeutics	2.00	Hold	$10.25	626.95% Upside
KZIA Novogen	2.71	Moderate Buy	$26.33	93.91% Upside
NXTC NextCure	2.25	Hold	$19.00	211.99% Upside
VNRX VolitionRX	2.40	Hold	$28.00	6,131.92% Upside

Current Analyst Ratings Breakdown

Latest VNRX, NXTC, ALLR, and KZIA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/26/2026	NXTC NextCure	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/17/2026	VNRX VolitionRX	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold
8/13/2026	NXTC NextCure	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/13/2026	KZIA Novogen	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$29.00
8/12/2026	NXTC NextCure	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/17/2026	ALLR Allarity Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	KZIA Novogen	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/15/2026	NXTC NextCure	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$20.00
7/15/2026	KZIA Novogen	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$34.00
7/7/2026	NXTC NextCure	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/1/2026	KZIA Novogen	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$34.00

(Data available from 8/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALLR Allarity Therapeutics	$320K	70.10	N/A	N/A	$0.22 per share	6.41
KZIA Novogen	$30K	746.90	N/A	N/A	($5.34) per share	-2.54
NXTC NextCure	N/A	N/A	N/A	N/A	$3.36 per share	N/A
VNRX VolitionRX	$1.73M	3.55	N/A	N/A	($2.46) per share	-0.18

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALLR Allarity Therapeutics	-$11.23M	-$0.78	N/A	N/A	N/A	N/A	-152.77%	-46.50%	11/13/2026 (Estimated)
KZIA Novogen	-$13.41M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	9/4/2026 (Estimated)
NXTC NextCure	-$55.84M	-$8.70	N/A	N/A	N/A	N/A	-154.62%	-100.19%	11/4/2026 (Estimated)
VNRX VolitionRX	-$23.36M	-$0.56	N/A	N/A	N/A	-1,043.12%	N/A	-303.75%	11/12/2026 (Estimated)

Latest VNRX, NXTC, ALLR, and KZIA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/4/2026	N/A	KZIA Novogen	-$0.65	N/A	N/A	N/A	$0.13 million	N/A
8/14/2026	Q2 2026	ALLR Allarity Therapeutics	-$0.25	-$0.21	+$0.04	-$0.21	N/A	N/A
8/13/2026	Q2 2026	VNRX VolitionRX	-$0.5675	-$0.85	-$0.2825	-$0.85	$0.42 million	$0.40 million
8/6/2026	Q2 2026	NXTC NextCure	-$1.95	-$2.80	-$0.85	-$2.80	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALLR Allarity Therapeutics	N/A	N/A	N/A	N/A	N/A
KZIA Novogen	N/A	N/A	N/A	N/A	N/A
NXTC NextCure	N/A	N/A	N/A	N/A	N/A
VNRX VolitionRX	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALLR Allarity Therapeutics	N/A	1.11	1.11
KZIA Novogen	N/A	2.87	N/A
NXTC NextCure	N/A	3.47	3.47
VNRX VolitionRX	N/A	0.30	0.30

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALLR Allarity Therapeutics	11.53%
KZIA Novogen	30.89%
NXTC NextCure	42.65%
VNRX VolitionRX	8.09%

Insider Ownership

Company	Insider Ownership
ALLR Allarity Therapeutics	0.16%
KZIA Novogen	1.00%
NXTC NextCure	11.90%
VNRX VolitionRX	6.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALLR Allarity Therapeutics	10	15.91 million	15.89 million	Not Optionable
KZIA Novogen	12	1.65 million	1.64 million	No Data
NXTC NextCure	90	3.61 million	3.18 million	No Data
VNRX VolitionRX	80	13.65 million	12.71 million	Not Optionable

VNRX, NXTC, ALLR, and KZIA Headlines

Recent News About These Companies

VolitionRX (NYSEAMERICAN:VNRX) Stock Price Crosses Below 50-Day Moving Average - What's Next?

August 27 at 3:01 AM | americanbankingnews.com

VolitionRX Earnings Call: Scientific Momentum Meets Cash Risks

August 26 at 8:31 PM | tipranks.com

VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets

August 26 at 9:17 AM | prnewswire.com

Volition Announces Landmark Clinical Validation of Nu.Q® NETs Biomarker in Sepsis

August 26 at 8:17 AM | prnewswire.com

Volition (VNRX) Q2 2026 Earnings Call Transcript

August 20, 2026 | finance.yahoo.com

Volitionrx Ltd Stock Price History

August 20, 2026 | investing.com

VolitionRx Limited (VNRX) Q2 2026 Earnings Call Transcript

August 14, 2026 | seekingalpha.com

VolitionRx Limited Announces Second Quarter 2026 Financial Results and Business Update

August 13, 2026 | prnewswire.com

VolitionRx Limited (VNRX) Stock Major Holders - Yahoo Finance

August 13, 2026 | finance.yahoo.com

Volition Demonstrates Utility of Rapid, Point-of-Care Finger-Prick Test in Sepsis Patients

August 12, 2026 | prnewswire.com

VolitionRx Limited Schedules Second Quarter 2026 Earnings Conference Call and Business Update

August 11, 2026 | prnewswire.com

Volition Reports Publication of First Peer Reviewed Paper on New Capture-Seq™ Liquid Biopsy Technology

August 5, 2026 | prnewswire.com

Volition Advances Nu.Q® NETs Platform Towards Commercialization

July 30, 2026 | prnewswire.com

Volitionrx Ltd (VNRX) Stock Forecast & Price Target

July 28, 2026 | investing.com

VolitionRx Shareholders Approve Governance and Capital Changes

July 24, 2026 | theglobeandmail.com

VolitionRx (VNRX) Stock Gets Fair Value Boost As Analysts Split On Nu.Q Execution

July 11, 2026 | finance.yahoo.com

VolitionRx Announces Data Showing the Prognostic Value of its Nu.Q® Cancer Test

July 7, 2026 | prnewswire.com

VolitionRx Limited: VolitionRx Announces Collaboration with Sysmex

June 17, 2026 | finanznachrichten.de

VolitionRx partners with Sysmex to optimize Nu.Q® NETs assay

June 17, 2026 | msn.com

VolitionRx Announces Collaboration with Sysmex

June 17, 2026 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VNRX, NXTC, ALLR, and KZIA Company Descriptions

Allarity Therapeutics NASDAQ:ALLR

$1.41 +0.03 (+2.17%)

As of 08/28/2026 04:00 PM Eastern

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.

Novogen NASDAQ:KZIA

$13.58 -3.32 (-19.64%)

As of 08/28/2026 04:00 PM Eastern

Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company's lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

NextCure NASDAQ:NXTC

$6.09 +0.06 (+1.00%)

As of 08/28/2026 04:00 PM Eastern

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.

VolitionRX NYSEAMERICAN:VNRX

$0.45 -0.05 (-10.32%)

As of 08/28/2026 04:10 PM Eastern

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VNRX, NXTC, ALLR, and KZIA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VNRX, NXTC, ALLR, and KZIA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VNRX, NXTC, ALLR, and KZIA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VNRX, NXTC, ALLR, and KZIA Company Descriptions

Allarity Therapeutics NASDAQ:ALLR

Novogen NASDAQ:KZIA

NextCure NASDAQ:NXTC

VolitionRX NYSEAMERICAN:VNRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VNRX, NXTC, ALLR, and KZIA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VNRX, NXTC, ALLR, and KZIA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VNRX, NXTC, ALLR, and KZIA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VNRX, NXTC, ALLR, and KZIA Company Descriptions

Allarity Therapeutics NASDAQ:ALLR

Novogen NASDAQ:KZIA

NextCure NASDAQ:NXTC

VolitionRX NYSEAMERICAN:VNRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools